- Rigel Pharmaceuticals ( NASDAQ: RIGL ) reported preliminary Q4 total revenue of about $51.3M, well ahead of analysts estimate of $21.65M.
- ( RIGL ) is up 5.6% before the bell.
- The Q4 total revenue includes Tavalisse preliminary net product sales of about $21.9M and Rezlidhia preliminary net product sales of about $0.9M.
- "In the fourth quarter of 2022, a total of 2,417 bottles of TAVALISSE were sold in the U.S., 2,196 of which were shipped directly to patients and clinics, representing the highest daily bottles shipped to patients and clinics in a quarter since launch," the company said.
- Rezlidhia, which became commercially available in the U.S. on December 22, reported sales of a total of 64 bottles in the U.S.
- Contract revenues for Q4 is expected to be about $28.5M, consisting of $26.5M in contract revenue from collaborations and $2M in government contract revenue.
- The company expects to report cash of about $58.2M.
For further details see:
Rigel Pharma rises as preliminary Q4 revenue above estimates